Purpose Guidelines discourage chronic benzodiazepines and related Z drugs (BZD/Zs) for sleep problems. However, prevalence among nursing home residents remains high. Discontinuing these drugs is widely recommended but seems difficult to implement. The aim of our study was to evaluate the overall feasibility in the nursing home, in terms of willingness towards discontinuation and success rate at 8 months, together with the impact on withdrawal symptoms, change in sleep quality, quality of life and medication use. Methods In a convenience sample of five nursing homes (823 residents), we included cognitively competent residents with chronic BZD/Z use for insomnia. We investigated sleep quality [with Pittsburgh Sleep Quality Index (PSQI)], quality of life (EQ-5D) and withdrawal symptoms [Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ)]. Success rate was analysed with survival analysis. Results Of the 135 eligible residents, both general physician (GP) and resident were willing to initiate discontinuation in 38 residents. Reasons for refusing to initiate discontinuation among GPs was the unmotivated patient and among residents the reluctance towards change. At 8 months, 66.0 % were successful discontinuers, with the subjective PSQI component evolving favourably (p=0.013) and a decreasing number of midnight awakenings (p=0.041). In the relapse group (n=13), the quality of life decreased (p=0.012), with mainly an increase of problems with activities and pain/discomfort. In both groups, the withdrawal symptoms, functionality and medication use did not change. Conclusion Discontinuation of chronic BZD/Z use is feasible in the nursing home setting without noticeable withdrawal symptoms, without a switch in medication use, without detrimental effect on quality of life and with a positive effect on the self-perceived sleep quality.
Introduction
Benzodiazepines and related Z drugs (BZD/Zs) are the most frequently used symptomatic treatment for sleep difficulties in older adults [1] . International guidelines discourage the chronic use of these BZD/Zs, because of the lack of long-term effectiveness, the risk of dependence, tolerance and withdrawal syndromes [2] [3] [4] . Though there were several campaigns and guidelines issued (the UK report in 1988 [5] , US reconciliation act in 1987 [6] and a more recent report in Belgium [7] ), the prevalence of chronic BZD/Z use remains high, particularly in the nursing home setting (prevalence ranges in European nursing homes from 28 % to more than 50 % [8] [9] [10] [11] ).
Discontinuing BZD/Zs is widely advised but seems difficult to implement [12, 13] . There is no consensus on the optimal tapering strategy [12, 14] , with options varying from abrupt discontinuation [15, 16] to tapering schedules of more than a year [17] .
A recent meta-analysis on reducing BZD/Zs in older people [18] included 16 studies in primary care [19] , geriatric wards [20, 21] and nursing homes [22, 23] and pointed at the effect of consultations and education of both prescribers and patients, both followed by a supervised withdrawal. In general, the studies in this analysis had a limited follow-up (three studies with follow-up of max 12 months and none in the nursing home), resulting in a lack of knowledge on long-term effectiveness (of specific interventions). The discontinuation of BZD/Zs in community-dwelling older people (aged 85 + years) appears to be possible [24] . The question remains whether BZD/Z discontinuation is feasible in the nursing home setting.
Several (non-randomised) studies have investigated BZD/ Z withdrawal in the nursing home setting and reported success rates of 87 % after 8 weeks [25] and a 50 % reduction in BZD/ Z use after 3 months [26] and 60 % after 1 year [27] . In those studies, there was a focus on the success rate (focus on residents already willing to discontinue). However, health policymakers should have an idea of the extent of the target population and the overall feasibility, including the willingness towards discontinuation in this setting.
Therefore, we designed a study in the nursing home setting to analyse both the feasibility in terms of willingness towards discontinuation and the success rate at 8 months of follow-up. We focused on cognitively capable residents with chronic BZD/Z use for sleep problems. Secondly, we investigated possible withdrawal symptoms and its impact on sleep quality and on the quality of life.
Methods

Design
This pilot study with a follow-up of 8 months investigated the overall feasibility of a discontinuation process of chronically used BZD/Zs in cognitively competent nursing home residents. The analysis of overall feasibility was divided into the willingness to initiate a discontinuation both among general physicians (GPs) and residents and the success rate in those residents who started discontinuation. We focused on BZD/Z use for sleep problems and explored possible withdrawal symptoms and the evolution of sleep quality and quality of life.
Setting
The Belgian long-term residential care structure consists of residential or nursing homes for older people, which offers a home replacement with or without nursing care. Governance of nursing homes for older people is either public (community health services) or private (predominantly non-profit) with little difference in quality of care. Oftentimes, the resident retains his/her former GP, resulting in an average of 32 consulting GPs per nursing home. The point prevalence of dementia among residents is approximately 50 % with considerable variation between nursing homes [28] .
Inclusion and exclusion criteria
In a convenience sample of five Belgian nursing homes, all cognitively competent residents were screened for inclusion (September 2012 until July 2013).
Eligible residents had established the chronic use of benzodiazepines or Z drugs for insomnia (administered daily at bedtime for at least 3 months) and were cognitively competent, which was confirmed with a Katz disorientation score of 1 or 2 (disorientation in time and place ranging from 1 = no disorientation to 4 = severe) [29] .
We excluded residents who were critically ill or had a fatal diagnosis with short life expectancy and residents who used a benzodiazepine during the day (for the indication anxiety) or used a sedative antidepressant (trazodone, amitriptyline, mirtazapine) or phytotherapy as co-medication.
Willingness to initiate discontinuation in chronic BZD/Z use (GP and resident)
One part of the overall feasibility focused on investigating how many GPs and residents were willing to initiate discontinuation.
The GP of the eligible resident received a recruitment letter. In this letter, the GP saw the name of his patient and the prescribed BZD/Z with the dose. In this recruitment letter, we asked the GP for the duration of BZD/Z use and whether he/she was willing to initiate a discontinuation in this particular resident. In case the GP did not want to initiate discontinuation, he/she could indicate the reason(s) among the following options: psychiatric problems or major depression, specific sleep disorders, specific medication inducing insomnia (e.g. psychotropic drugs, thyroids), BZD/Z used as anxiolytic or muscle relaxant, not feasible because of failed prior attempt(s), not feasible because of the lack of the resident's motivation and other reasons.
All residents, whose GP agreed to initiate discontinuation, were informed and asked for their willingness to discontinue their BZD/Z (informed consent).
Success rate of discontinuation process
In cases where both the GP and resident agreed, the discontinuation was initiated. Because of our naturalistic study design, we did not implement a strict discontinuation schedule and used no substitution or alternatives. The GP was responsible for the discontinuation, but we proposed a possible discontinuation schedule to the GP in the recruitment letter (25 % reduction per week or per 2 weeks). The successful discontinuation rate 8 months after inclusion was our main outcome parameter. We documented relapse and its reason (sleep problems during or after withdrawal, loss of motivation and others).
Data collection
We performed data collection at baseline, 2 months and 8 months after baseline, except for withdrawal symptoms (at baseline and after discontinuation). As our sample was a geriatric population, the researcher (J.B.) assisted residents with the recording and rating of the questionnaires.
Demographic data was obtained from the resident's record and medication data from the medication chart. Based on the Anatomical Therapeutic and Chemical (ATC) classification [30] , we selected the classes N05BA (anxiolytics), N05CD (hypnotics) and N05CF (Z drugs) as BZD/Z use. We divided the BZDs and Z drugs according to half-life in short/ intermediate (t ½ <24 h) and long acting (t ½ >=24 h) based on a reference source [31] . We also used the defined daily dose (DDD) to compare dosages. The total number of chronically used medications as well as that of possibly interfering medication such as antidepressants (ATC N06A), antipsychotics (ATC N05A), anti-dementia drugs (ATC N06D), antiParkinson (ATC N04) drugs and pain medication (ATC N02) were recorded. Functional characteristics were scored using the Katz scale [29] . This instrument is mandatory in Belgian nursing homes. The first part of this instrument scores six activities of daily living (ADLs) from 1 (independent) to 4 (totally dependent). The second part scores disorientation in time and place ranging from 1 (no disorientation) to 4 (severe) and was used in the inclusion of eligible residents (residents with score 1 or 2). Depressive feelings were scored with the eight-item Geriatric Depression Scale (GDS), which is an abbreviated version of the GDS 30 [32] and especially designed and validated for nursing home residents [33, 34] . A score of 3 or more on the GDS-8 is indicative for depressive symptoms. Additionally, we recorded hospital admissions and falls by checking the medical file and recorded hearing and visual impairment and frequent pain (by using a yes or no question).
The validated Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) was used [35] to detect withdrawal symptoms. This self-report questionnaire measures 20 symptoms. The three answer possibilities (no-moderate-severe) are linked to a rating of 0, 1 or 2, with higher scores indicating more withdrawal symptoms (maximum score is 40).
The sleep quality was analysed with the Pittsburgh Sleep Quality Index (PSQI) [36] , a self-rated questionnaire which investigates global sleep quality and sleep disturbances (Dutch translation [37] ). The seven components of the PSQI are scored from 0 to 3, yielding a total score ranging from 0 to 21, where higher scores indicate worse sleep quality. A total PSQI score of more than 5 is a widely used cut-off that indicates poor sleep quality. Because in this study we wanted to compare sleep quality before and after discontinuation, we left out the PSQI component sleep medication in the total PSQI score (adjusted PSQI, with a score ranging between 0 and 19). We also reported the component subjective sleep quality as perceived by the resident himself (scored from 0 to 3).
Quality of life was assessed with the descriptive part of the EQ-5D-3L, which is a standardised measure of health status developed by the EuroQol Group [38] and validated in nursing home residents [39] . The EQ-5D-3L descriptive system comprises the following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which is scored from 1 (no problems) to 2 (some problems) to 3 (extreme problems). The descriptive profile score is converted into the EQ-5D index [40] , with higher scores indicating better health.
Ethical considerations
This observational study was approved by the ethics committee of the University Hospital of Ghent (registration number B670201213943). Each nursing home received information and gave approval to screen the nursing home population. The GP had to approve the resident's inclusion. Each resident, included in our study, received oral and written information and gave consent.
Statistics
We used descriptive statistics to analyse the feasibility of discontinuation and survival analysis to analyse the success rate of discontinuation during an 8-month period. The outcome parameters, i.e. withdrawal symptoms, sleep quality, quality of life, functionality and medication use, were described and compared between the discontinuers and the controls, and also between the successful discontinuers and the relapse group. Because of the small number of residents in each group, we used non-parametric statistics (Mann-Whitney U test for the comparison of categorical variables between groups and Kruskal-Wallis test for paired analysis).
Results
Willingness to stop
In the five nursing homes with a total of 823 residents, our exclusion of residents with known dementia or disorientation (n=558) and of residents with BZD use for anxiety or other sleep enhancing medication (n=130) resulted in 135 eligible residents (16 %) (Fig. 1, flow chart) .
The GPs of those 135 residents indicated that a discontinuation was feasible in 51 residents by returning a positive recruitment letter. For 13 residents, the GP did not respond to the recruitment letter. The reasons why GPs (n=71) were not willing to initiate a discontinuation are summed in Fig. 2 . More than half of the GPs indicated that there was a lack of motivation of the resident himself (56 %). In 18 %, the failure of a previous attempt was the reason not to initiate a discontinuation.
Of those 51 residents, where the GP agreed, 13 residents refused to start the discontinuation of their BZD/Z. The main reason (12/13) was the reluctance towards change (too old, I sleep well). In total, 38 residents gave informed consent and were included in the discontinuation study.
The most frequently used BZD/Zs in the 38 discontinuers were lormetazepam (36.8 %) and lorazepam (21.1 %), 37 residents used a short-acting BZD/Z, and the median prescribed dose was one DDD (range 0.10-2.00).
Success rate of intervention (survival analyse)
After 2 months, 25/38 residents were BZD/Z free, 7/38 residents reduced their dose, and 6/38 residents relapsed. After 8 months, one resident of the 25 successful discontinuers relapsed, one deceased, and one additional resident stopped BZD/Z. The median duration of the discontinuation process was 21 days (range 7-88 days).
The reasons why residents were not successful in their discontinuation was because of sleep problems during the discontinuation (n=6/13) and overall loss of motivation (n= 5/13). Real increase in withdrawal symptoms (as scored by the BWSQ) was not observed. Of the 24 residents who were successfully weaned after 8 months, one person took placebo and one person used an antihistaminic (hydroxyzine) as needed.
The survival analysis revealed that 66.0 % were successful in completely discontinuing BZD/Z use at 8 months. If we also considered the residents who decreased their BZD/Z dose as successful, the success rate increased to 82.0 % (Fig. 3) .
Baseline comparison between successful discontinuation group and relapse group At baseline, the successful discontinuers (n=25) and relapse group (n=13) were comparable on all demographic, clinical, institutional and medication characteristics (Table 1) as well as for baseline outcome parameters (sleep quality components, quality of life).
Impact of discontinuation on withdrawal symptoms
The mean BWSQ score among the 38 discontinuers evolved from 3.9 (SD 2.8, range 0-11) at baseline to 4.1 (SD 2.6, range 0-12) after discontinuation (p=0.865), indicating that there were no excess symptoms noticeable during withdrawal (Table 2 ). Both in successful (n=25) and relapse (n=13) groups, the withdrawal symptoms did not differ at baseline and did not change over time (p=0.175).
Among the 38 discontinuers, the most commonly reported symptoms incorporated in the BWSQ were muscle pain (49 % Fig. 1 Flow chart of the willingness to discontinue chronic benzodiazepine/Z drug use at baseline and 63 % afterwards), muscle twitching (41 and 37 %), loss of memory (41 and 32 %), pins and needles (35 and 39 %) and feeling depressed (32 and 37 %).
Impact of discontinuation on sleep quality
The total adjusted PSQI score in the successful discontinuers (n=24) was the same over the three time points 5.3 (SD 2.9), 5.1 (SD 2.6) and 5.3 (SD 3.3) at baseline, 2 months and after 8 months, respectively (difference between baseline and 8 months p=0.880). In the relapse group, this adjusted PSQI score evolved from 5.8 (SD 2.8) at baseline to 5.5 (SD 2.3) at 2 months and increased to 7.9 (SD 4.8) at 8 months (difference between baseline and 8 months p=0.075) ( Table 2) .
The subjective component in the PSQI questionnaire showed an overall improvement of the sleep quality in the successful discontinuers (from 1.25 at baseline to 0.88 at 8 months, p=0.013). In the relapse group, the subjective sleep quality evolved from 1.23 at baseline to 1.15 at 8 months, p= 0.739.
The total hours of sleep decreased over 8 months in the successful discontinuers from 8 h and 44 min at baseline to 8 h and 1 min at 8 months (p=0.031) and in the relapse group from 8 h and 24 min to 7 h and 1 min (p=0.019). The sleep latency increased over 8 months from 27 to 42 min (p=0.304) in the successful group and from 26 to 41 min (p=0.107) in the relapse group.
The number of midnight awakenings decreased significantly among the successful discontinuers (1.56 at baseline to 0.83 at 8 months, p=0.041). All other components of the PSQI did not change significantly.
Impact of discontinuation on other outcome parameters
The functionality (ADL score) or the number of chronic medications (BZD/Z not included) did not change in both groups over 8 months (p value=0.280) ( Table 2) .
The EQ-5D-3L index score did not evolve significantly in the successful discontinuers (from 0.439 to 0.456, p=0.879) ( Table 2 ). In the relapse group, quality of life decreased from 
Discussion
This discontinuation study in the nursing home setting showed that discontinuation of chronic BZD/Z use is feasible without noticeable withdrawal symptoms, without a switch in medication use, without a detrimental effect on quality of life and with a positive effect on the sleep quality. Our analysis at 8-month follow-up showed that 66 % succeeded in stopping their BZD/Z use. The success rate was enhanced to 82 % when we included everyone who decreased their dose. Nevertheless, the proportion of eligible residents was low and the recruitment was difficult. Our inclusion criteria provided a small sample of eligible residents (135/823). Recruiting residents of which both GP and resident agreed to initiate discontinuation reduced our sample further to 38/135. The most frequently indicated reason for refusing discontinuation among GPs was an unmotivated patient and among residents the reluctance towards change.
Strengths and limitations
Rational medication use also includes the discontinuation of drugs that are not really necessary or can cause harm [13, 41] . Because discontinuing medication in older adults is not yet a routine procedure and is especially difficult when it concerns chronic BZD/Zs for insomnia problems [12] , our study on the feasibility of discontinuing chronic BZD/Z use in the nursing home setting appears to be very relevant.
The major strength is our focus on the overall feasibility. Some studies investigated the general perceptions of chronic BZD/Z use among physicians [42] [43] [44] and patients [45] [46] [47] . Others focused on the discontinuation process [48, 49] . Our study combines those two important research topics in order to represent the overall feasibility: the willingness to initiate a discontinuation and whether this discontinuation can be successful for a longer period (8 months). This study was not intended to find the optimal tapering strategy; the GP was free to tailor the withdrawal to the needs of his/her patient as suggested in the literature [12] .
Another strength of this study lies in its pragmatic approach and easy translation to the real-life setting. However, several exclusion criteria limit the total generalizability. We excluded residents with dementia/disorientation because of the controversy towards medication withdrawal and because of the difficulty of monitoring study outcomes (withdrawal symptoms, sleep quality, etc.) in this patient group. This ethical hindrance has led to a paucity of valuable information, with no specific studies on BZD/Z withdrawal in this patient group [50] . From a previous study in the Belgian nursing homes [51] , we knew that 59 % of the chronic BZD/Z use is intended to treat the sole indication, insomnia. All guidelines agree on the time-limited use for this indication. Because there is uncertainty on the appropriateness of long-term use of BZD/Z for anxiety disorder [52] and other indications (such as epilepsy, muscle spasm, etc.) and because we were not able to offer alternative (non-)pharmacological therapy, we excluded residents that used the BZD/Z for anxiety. Because our focus is on BZD/Z use, we excluded residents that used other hypnotic medications, such as trazodone, or other antidepressants and phytotherapy. Though inherent to a pilot study, our small sample size is an important limitation. Moreover, we had no control group which limits the interpretations towards differences in outcome measurements. Although it would be of great value to have a comparable group of residents who do not stop their BZD/Z and serve as controls, no study has been able to include this because of recruitment difficulties. Our large cascade limits the possibilities of comparison and forces us to use non-parametric statistics. However, we had a very small number of lost to follow-up. We did collect the number of chronic medication and focused on psychotropic medication, but we had no information on comorbidities. Recall bias could not be avoided, as we questioned the withdrawal symptoms after the completion of the discontinuation process.
Main discussion
Overall feasibility: willingness and success rate Of the total sample of 135 eligible residents, only 28 % were willing to initiate a discontinuation. This finding confirmed the results of a previous survey among GPs and nurses investigating willingness to stop [51] . This older population with years (even decades) of daily BZD/Z use [53] and with limited prospects for clinical improvement expresses a lack of motivation and even reluctance towards discontinuation [43, 54] . Because we were ethically obliged to first ask the GP for agreement to initiate withdrawal, we could not know whether the GP had discussed discontinuation with his/her patient or he just assumed a lack of motivation. Nevertheless, some patients are susceptible to change. Therefore, it is advised to routinely raising the issue and negotiating dose reduction [55, 56] .
Of the residents who initiated withdrawal, 66 % succeeded in withdrawing their BZD/Z fully at 8 months and an [14, 57] .
Outcome parameters
In our study, the residents with chronic BZD/Z for sleep problems used low dosages and there was no increase in withdrawal symptoms noticeable. The BWSQ is intended to detect change in different symptoms. We found an already high frequency of several symptoms at baseline (muscle pain, muscle twitching, etc.), but we did not find a change during withdrawal. However, there were some residents who relapsed due to sleep problems during or after withdrawal (n= 6/13), indicating possible rebound insomnia [58] .
Residents with successful discontinuation reported a better sleep quality than before the discontinuation. We found a significant reduction of the total hours of sleep. Also, the number of midnight awakenings was significantly reduced. It is known that BZD/Zs shorten the sleep latency and change sleep architecture at the expense of the deep restorative stages of sleep [59] . Stopping the chronic BZD/Z use could imply that the sleep rehabilitates and becomes less fractionated and less vulnerable to pain, noise and other potential distractions.
There was no change in quality of life and functionality among the successful discontinuers. The quality of life index (EQ-5D-3L) did decrease significantly in the relapse group but was still higher than in the successful group.
Medication substitution is a common concern [60] [61] [62] , but in our study, there was no increase in medication use or switch towards other (psychotropic/sedative) medications (except for intermittent use of a placebo or antihistaminic in two residents).
Implications for research
More research is needed to decide whether a discontinuation campaign in this subpopulation is cost-effective and which interventions can lift barriers and increase the willingness to engage in discontinuation, both in patients and in physicians.
In order to confirm with sufficient power that discontinuation of BZD/Z leads to better sleep quality, prospective studies with sufficient sample size and a random or matched control group should be set up.
Finally, the feasibility, success rate and outcome should also be investigated in residents with dementia/ disorientation and in people with BZD/Zs used for the indication anxiety, not only in the nursing home setting but also in ambulatory care.
Implications for practice
The approach to discontinuation in our study can be implemented on a larger scale. Nursing homes may be a protected environment where GPs (and other care personnel) can familiarize with discontinuation efforts, gain confidence and even extend these efforts to the large community of home dwelling older adults. Informing all prescribers, caregivers and patients of the negative effects of chronic BZD/Z use and the positive prospects of discontinuation together with educating prescribers in motivational techniques could impact the overall willingness.
When taking care of the oldest old, especially in the nursing home, multiple actors are responsible for the medication use so it is important to include nurses, physicians, pharmacists and management, taking into account powerful barriers towards willingness to change.
